Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trial

CONCLUSIONS: Among patients with severe COVID-19 treated with corticosteroids and with exclusion of pulmonary embolism at hospital admission for most, risks of mortality, thrombotic outcomes, and DIC were low at 30 days. The lack of benefit of therapeutic anticoagulation was too imprecise for definite conclusions.PMID:35599701 | PMC:PMC9116142 | DOI:10.1002/rth2.12712

Source: Thrombosis and Haemostasis - May 23, 2022 Category: Hematology Authors: Marc Blondon Sara Cereghetti J érôme Pugin Christophe Marti Pauline Darbellay Farhoumand Jean-Luc Reny Alexandra Calmy Christophe Combescure Lucia Mazzolai Olivier Pantet Zied Ltaief Marie M éan Sara Manzocchi Besson S éverin Jeanneret Hans Stricker H Source Type: research